Brii Biosciences and VBI Vaccines present positive data from completed phase 1b / 2a study of BRII-179 (VBI-2601) in patients with chronic hepatitis B at the International Liver Congress (ILC) 2021

Data show that BRII-179 (VBI-2601) induced both B-cell (antibody) and T-cell responses in chronically infected hepatitis B (HBV) patients and was well tolerated with no safety observations made were

Results support the further clinical evaluation of BRII-179 (VBI-2601) as an immunomodulator in combination with other treatment modalities as a potential functional cure for chronic HBV infection

Abstract selected for inclusion in the “Best of ILC” presentation at EASL 2021

Brii Biosciences (“Brii Bio”) and VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”) today announced the final results of a Phase 1b / 2a study of BRII-179 (VBI-2601), a novel recombinant, protein-based immunotherapy candidates in patients with chronic hepatitis B virus (HBV) infection. The data from the study, which examined the safety, antiviral activity, and immunogenicity of BRII-179 (VBI-2601) alone or in combination with interferon-alpha (IFN-α) as a co-adjuvant, showed that the investigational immunotherapeutic drug did not cirrhotic chronic hepatitis B patients on nucleos